One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06936254

Acronym

VIM vs NST

Enrollment

Registered

2025-04-20

Start date

2025-04-30

Completion date

2026-09-30

Last updated

2025-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Brain Stimulation, Parkinson Disease (PD)

Brief summary

This study compares the effects of deep brain stimulation (DBS) of the thalamic VIM nucleus versus the subthalamic nucleus (STN) on the levodopa equivalent daily dose (LEDD) in patients with Parkinson's disease. The goal is to determine whether VIM stimulation, typically used for tremor, can also reduce medication needs. It hypothesizes that STN stimulation leads to greater LEDD reduction, but VIM may offer moderate benefits in selected case

Detailed description

Thesis Summary: Deep brain stimulation (DBS) is a well-established therapeutic option for patients with advanced Parkinson's disease. The two most commonly targeted structures are the subthalamic nucleus (STN) and the ventral intermediate nucleus (VIM) of the thalamus. While STN stimulation is known to allow a significant reduction in the levodopa equivalent daily dose (LEDD), the effects of VIM stimulation on medication dosage remain less clear, particularly in patients selected for predominant tremor. Objectives: To compare the evolution of LEDD one year after DBS targeting the VIM versus the STN in patients with Parkinson's disease. To assess whether VIM stimulation also enables a meaningful reduction in dopaminergic medication. To contribute to refining surgical indications based on the patient's clinical profile. Hypotheses: STN stimulation leads to a greater reduction in LEDD compared to VIM stimulation. VIM stimulation, though primarily used for tremor control, may result in moderate LEDD reduction in specific patient profiles. Surgical target selection should be personalized, considering not only motor symptom control but also the impact on medication requirements.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Parkinson's disease * Underwent surgery for subthalamic nucleus (STN) or ventral intermediate nucleus (VIM) deep brain stimulation * Surgery performed at CHRU of Nancy * Surgery performed between 2014 (DxCare implementation) and 2024

Exclusion criteria

* No clinical diagnosis of Parkinson's disease * No initial dopaminergic treatment * Surgery not performed at CHRU of Nancy * Death within 1 year following surgery

Design outcomes

Primary

Measure	Time frame	Description
Change in the levodopa equivalent daily dose (LEDD) between Parkinson's disease patients undergoing deep brain stimulation (DBS) targeting the VIM thalamic nucleus versus the STN.	The primary endpoint, which is the change in levodopa equivalent daily dose (LEDD), will be measured one year post-surgery in both the VIM and STN DBS groups.	To compare the one-year change in the levodopa equivalent daily dose (LEDD) between Parkinson's disease patients undergoing deep brain stimulation (DBS) targeting the VIM thalamic nucleus versus the STN.

Countries

France

Contacts

Primary ContactAmory Jardel

a.jardel@chru-nancy.fr+33 6 88 45 13 20

Outcome results